{"id":"W4392383154","doi":"10.1038/s41598-024-55320-1","title":"Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study","year":2024,"lang":"en","type":"article","venue":"Scientific Reports","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Theratechnologies (Canada); University of Ottawa; Ottawa Hospital; Providence Health Care; Canada Research Chairs; University of New Brunswick; University of Toronto","funders":"","keywords":"Immunogenicity; Medicine; Vaccination; Titer; Seroconversion; Tolerability; Neutralizing antibody; Immunology; Virology; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Coronavirus disease 2019 (COVID-19); Clinical trial; Antibody; Adverse effect; Internal medicine; Disease; Infectious disease (medical specialty)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003419097,0.001215005,0.002080176,0.0003493563,0.0003196839,0.0008550484,0.0005597635,0.001340719,0.003381484],"category_scores_gemma":[0.002783646,0.0004927337,0.001030077,0.0003041815,0.0009499803,0.0008621254,0.0002823211,0.001868563,0.0006202254],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004934187,"about_ca_system_score_gemma":0.001151683,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002462277,"about_ca_topic_score_gemma":0.0004079677,"domain_scores_codex":[0.9982408,0.0009517919,0.0001433428,0.0002612978,0.0002106472,0.0001920696],"domain_scores_gemma":[0.9984968,0.0004037272,0.0003961956,0.0002440448,0.0001876342,0.0002716038],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8578115,0.0601892,0.001239117,0.0005237386,0.0004595386,0.0001003692,0.0001726742,0.0004790068,0.05805175,0.0002017175,0.0005333803,0.02023803],"study_design_scores_gemma":[0.1805177,0.8096529,0.002931494,0.00002437474,0.0002280517,0.0000610597,0.00004156875,0.0003818299,0.00479703,0.0001387467,0.00120673,0.00001846281],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929963,0.000578868,0.001109443,0.00009394802,0.000247441,0.004007425,0.0003152573,0.00004365324,0.000607679],"genre_scores_gemma":[0.9859737,0.0008344981,0.002668925,0.0003611685,0.0003596409,0.006746763,0.0007429311,0.00003166484,0.002280662],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003419097,"threshold_uncertainty_score":0.01808214,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04375368862732793,"score_gpt":0.3703660444144287,"score_spread":0.3266123557871007,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}